Tags

Type your tag names separated by a space and hit enter

Hemodialysis and erythrocyte epoxy fatty acids.
Physiol Rep. 2020 Oct; 8(20):e14601.PR

Abstract

Fatty acid products derived from cytochromes P450 (CYP) monooxygenase and lipoxygenase (LOX)/CYP ω/(ω-1)-hydroxylase pathways are a superclass of lipid mediators with potent bioactivities. Whether or not the chronic kidney disease (CKD) and hemodialysis treatments performed on end-stage renal disease (ESRD) patients affect RBC epoxy fatty acids profiles remains unknown. Measuring the products solely in plasma is suboptimal. Since such determinations invariably ignore red blood cells (RBCs) that make up 3 kg of the circulating blood. RBCs are potential reservoirs for epoxy fatty acids that regulate cardiovascular function. We studied 15 healthy persons and 15 ESRD patients undergoing regular hemodialysis treatments. We measured epoxides derived from CYP monooxygenase and metabolites derived from LOX/CYP ω/(ω-1)-hydroxylase pathways in RBCs by LC-MS/MS tandem mass spectrometry. Our data demonstrate that various CYP epoxides and LOX/CYP ω/(ω-1)-hydroxylase products are increased in RBCs of ESRD patients, compared to control subjects, including dihydroxyeicosatrienoic acids (DHETs), epoxyeicosatetraenoic acids (EEQs), dihydroxydocosapentaenoic acids (DiHDPAs), and hydroxyeicosatetraenoic acids (HETEs). Hemodialysis treatment did not affect the majority of those metabolites. Nevertheless, we detected more pronounced changes in free metabolite levels in RBCs after dialysis, as compared with the total RBC compartment. These findings indicate that free RBC eicosanoids should be considered more dynamic or vulnerable in CKD.

Authors+Show Affiliations

Experimental and Clinical Research Center (ECRC), A Joint Institution Between the Charité University Medicine and Max Delbrück Center (MDC) for Molecular Medicine, Berlin-Buch, Germany. HELIOS Klinikum Berlin-Buch, Berlin, Germany.Experimental and Clinical Research Center (ECRC), A Joint Institution Between the Charité University Medicine and Max Delbrück Center (MDC) for Molecular Medicine, Berlin-Buch, Germany. Max Delbrück Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin, Germany.Experimental and Clinical Research Center (ECRC), A Joint Institution Between the Charité University Medicine and Max Delbrück Center (MDC) for Molecular Medicine, Berlin-Buch, Germany.LIPIDOMIX GmbH, Berlin, Germany.LIPIDOMIX GmbH, Berlin, Germany.Experimental and Clinical Research Center (ECRC), A Joint Institution Between the Charité University Medicine and Max Delbrück Center (MDC) for Molecular Medicine, Berlin-Buch, Germany. Nephrology/Intensive Care Section, Charité Campus Virchow, Berlin, Germany. Department of Internal and Geriatric Medicine, University Medicine Greifswald, Greifswald, Germany.Nephrology/Intensive Care Section, Charité Campus Virchow, Berlin, Germany.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

33112511

Citation

Gollasch, Benjamin, et al. "Hemodialysis and Erythrocyte Epoxy Fatty Acids." Physiological Reports, vol. 8, no. 20, 2020, pp. e14601.
Gollasch B, Wu G, Liu T, et al. Hemodialysis and erythrocyte epoxy fatty acids. Physiol Rep. 2020;8(20):e14601.
Gollasch, B., Wu, G., Liu, T., Dogan, I., Rothe, M., Gollasch, M., & Luft, F. C. (2020). Hemodialysis and erythrocyte epoxy fatty acids. Physiological Reports, 8(20), e14601. https://doi.org/10.14814/phy2.14601
Gollasch B, et al. Hemodialysis and Erythrocyte Epoxy Fatty Acids. Physiol Rep. 2020;8(20):e14601. PubMed PMID: 33112511.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Hemodialysis and erythrocyte epoxy fatty acids. AU - Gollasch,Benjamin, AU - Wu,Guanlin, AU - Liu,Tong, AU - Dogan,Inci, AU - Rothe,Michael, AU - Gollasch,Maik, AU - Luft,Friedrich C, PY - 2020/07/03/received PY - 2020/09/13/revised PY - 2020/09/14/accepted PY - 2020/10/29/pubmed PY - 2020/10/29/medline PY - 2020/10/28/entrez KW - chronic kidney disease (CKD) KW - dialysis KW - erythrocytes KW - fatty acids KW - lipidomics SP - e14601 EP - e14601 JF - Physiological reports JO - Physiol Rep VL - 8 IS - 20 N2 - Fatty acid products derived from cytochromes P450 (CYP) monooxygenase and lipoxygenase (LOX)/CYP ω/(ω-1)-hydroxylase pathways are a superclass of lipid mediators with potent bioactivities. Whether or not the chronic kidney disease (CKD) and hemodialysis treatments performed on end-stage renal disease (ESRD) patients affect RBC epoxy fatty acids profiles remains unknown. Measuring the products solely in plasma is suboptimal. Since such determinations invariably ignore red blood cells (RBCs) that make up 3 kg of the circulating blood. RBCs are potential reservoirs for epoxy fatty acids that regulate cardiovascular function. We studied 15 healthy persons and 15 ESRD patients undergoing regular hemodialysis treatments. We measured epoxides derived from CYP monooxygenase and metabolites derived from LOX/CYP ω/(ω-1)-hydroxylase pathways in RBCs by LC-MS/MS tandem mass spectrometry. Our data demonstrate that various CYP epoxides and LOX/CYP ω/(ω-1)-hydroxylase products are increased in RBCs of ESRD patients, compared to control subjects, including dihydroxyeicosatrienoic acids (DHETs), epoxyeicosatetraenoic acids (EEQs), dihydroxydocosapentaenoic acids (DiHDPAs), and hydroxyeicosatetraenoic acids (HETEs). Hemodialysis treatment did not affect the majority of those metabolites. Nevertheless, we detected more pronounced changes in free metabolite levels in RBCs after dialysis, as compared with the total RBC compartment. These findings indicate that free RBC eicosanoids should be considered more dynamic or vulnerable in CKD. SN - 2051-817X UR - https://www.unboundmedicine.com/medline/citation/33112511/Hemodialysis_and_erythrocyte_epoxy_fatty_acids L2 - https://doi.org/10.14814/phy2.14601 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.